Equillium (EQ) Accounts Payables (2017 - 2026)
Equillium (EQ) posted quarterly Accounts Payables of $1.3 million for Q1 2026, down 57.65% year-over-year from $3.1 million in Q1 2025, and up 71.52% quarter-over-quarter from $755000.0 in Q4 2025.
Equillium (EQ) Accounts Payables (2017 - 2026) Analysis & Trends
Equillium (EQ) has reported Accounts Payables for 10 consecutive years, with $1.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables fell 57.65% year-over-year to $1.3 million; the TTM figure through Mar 2026 stood at $1.3 million (down 57.65% YoY), while the FY2025 annual figure was $755000.0, down 71.79% from the prior year.
- Accounts Payables advanced to $1.3 million in Q1 2026 per EQ's latest filing, from $755000.0 in the prior quarter.
- Across five years, Accounts Payables topped out at $5.7 million in Q1 2023 and bottomed at $755000.0 in Q4 2025.
- Historically, Accounts Payables has averaged $3.4 million across 5 years, with a median of $3.6 million in 2023.
- Annual changes were most pronounced in 2022 — Accounts Payables jumped 224.65% — and 2025, when it plunged 71.79%.
- Equillium's Accounts Payables stood at $4.0 million in 2022, then grew by 18.36% to $4.7 million in 2023, then plunged by 43.15% to $2.7 million in 2024, then slumped by 71.79% to $755000.0 in 2025, then jumped by 71.52% to $1.3 million in 2026.
- Business Quant data shows EQ's Accounts Payables at $1.3 million in Q1 2026, $755000.0 in Q4 2025, and $1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Equillium | 263.86 Mn | 263.86 Mn | - | 850,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 850,000.00 |
| Mar 31, 2026 | 1.30 Mn |
| Dec 31, 2025 | 755,000.00 |
| Sep 30, 2025 | 1.08 Mn |
| Jun 30, 2025 | 4.81 Mn |
| Mar 31, 2025 | 3.06 Mn |
| Dec 31, 2024 | 2.68 Mn |
| Sep 30, 2024 | 3.67 Mn |
| Jun 30, 2024 | 4.49 Mn |
| Mar 31, 2024 | 2.78 Mn |
| Dec 31, 2023 | 4.71 Mn |
| Sep 30, 2023 | 3.64 Mn |
| Jun 30, 2023 | 3.03 Mn |
| Mar 31, 2023 | 5.69 Mn |
| Dec 31, 2022 | 3.98 Mn |
| Sep 30, 2022 | 2.47 Mn |
| Jun 30, 2022 | 5.09 Mn |
| Mar 31, 2022 | 4.21 Mn |
| Dec 31, 2021 | 1.23 Mn |
| Sep 30, 2021 | 2.67 Mn |